Add BrightSurf on Google Email

Science News for September 21, 2024


Environmental study highlights high levels of air and water pollution near industrial zones in Delta Nigeria

A study highlights significant air and water pollution near industrial zones in Delta, Nigeria, posing risks to human health and the environment. The analysis found elevated levels of pollutants, including particulate matter, sulfur dioxide, and heavy metals, affecting respiratory health and other health issues.

SourceMaximum Academic Press·JournalEmergency Management Science and Technology·TypeExperimental study·DateSep 21, 2024

Study highlights importance of dedicated exits for vulnerable populations in building evacuations

A study highlights the importance of dedicated exits for vulnerable populations during building evacuations, with findings suggesting that centrally located dedicated exits can improve evacuation efficiency. Dedicated exits are most beneficial in low to moderate crowd densities and should be carefully considered in high-density scenarios.

SourceMaximum Academic Press·JournalEmergency Management Science and Technology·TypeExperimental study·DateSep 21, 2024

Black patients with triple-negative breast cancer may be less likely to receive immunotherapy than white patients

A recent study found that Black patients with triple-negative breast cancer (TNBC) received immunotherapy at significantly lower rates than white patients. However, when they did receive immunotherapy, their overall survival rate was similar to that of white patients. The study suggests that socioeconomic factors may be the main barrie...

Study shows psychedelic drug psilocybin gives comparable long-term antidepressant effects to standard antidepressants, but may offer additional benefits

A 6-month study found that psilocybin offered similar improvements to SSRI escitalopram in depressive symptoms, but with greater social functioning and psychological connectedness. Psilocybin may offer an alternative for those not responding to SSRIs, but its benefits are still being studied.

SourceEuropean College of Neuropsychopharmacology·TypeRandomized controlled/clinical trial·DateSep 21, 2024